🔗 Share this article

While America proceeds with historic changes to its immunization recommendations, an unexpected name appears unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccines during the global health crisis and has zeroed in on alleged fatalities following COVID-19 vaccination in her brief position at the Food and Drug Administration.

Planned Changes to Childhood Vaccine Program

Agency leaders were set to reveal major changes to the pediatric vaccination calendar recently, synchronizing the US with Denmark’s national calendar, according to reports – a substantial departure that would place the US at odds with many the global community with little proof for improved outcomes. The planned update has been pushed back until the coming year.

Rather than the top vaccines chief, Dr. Høeg is set to address the audience at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth individual to head the division this calendar year.

A Shift at the FDA

This interim role could signify a strengthened alliance between the drug and biologics branches as Dr. Høeg and Prasad strengthen their influence at the agency – and it suggests a greater focus upon reevaluating previously authorized immunizations at the FDA.

The new acting director has repeatedly called for discontinuing some pediatric shot schedules in the US to become more in line with Denmark's approach, a society with universal health coverage and a population approximately the size of the state of Wisconsin.

In her initial comments, she has kept her attention on immunizations – typically the domain of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Questions Over Background

The appointee has little discernible track record in drug development, oversight or administrative roles, which has been typical for former heads of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for overseeing the CDER, remarked Jonathan Howard. “She’s never run a scientific study. She has no expertise in leading a major agency. She has no expertise in drug approvals.”

Previous directors of CBER would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, commented Janet Woodcock. “Clearly, she lacks the kind of background that former directors who headed CBER have had.”

The drug center has an immense portfolio at the agency, Woodcock emphasized.

“The public just pays attention on the novel medication approvals, but the generic program clears thousands of generic drugs. There’s a biosimilars program, non-prescription drug unit and other areas, and all of those have to be supervised,” Dr. Woodcock said. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a substantial leadership aspect to the role, which oversees over 5,000 employees. “It is a huge management job, if you execute it properly,” Woodcock added.

Agency Reaction and Contentious Initiatives

In response to questions about Høeg’s credentials and whether this appointment signifies increased cooperation among FDA leaders on vaccines, a press secretary responded that the “concerns rely on inaccurate premises”.

“This background matches the functions of her position,” the spokesperson said, pointing to the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg takes over the commissioner’s recently launched fast-track approval initiative, a controversial expedited medication authorization process that apparently troubled her preceding directors. “How are these drugs being selected for this fast-track system? Who makes the choices?” Howard said. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

Overall, he stated, “the agency appears to be shifting towards more relaxed rules of all drugs, except for immunizations.”

Public Past Work on Vaccines

Concerning immunizations, Høeg has a more established, if problematic, track record, Howard have noted. She published a research paper using unverified public submissions to assess the frequency of myocarditis following Covid vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccines are more dangerous than they are.

Part of her “policy goals” for the current administration featured altering regulations for new vaccines and discontinuing “optional” immunizations, she said post-election on a online show. At the FDA, Høeg has according to sources floated the idea of preventing young men from receiving Covid vaccines.

“She is an thorough ideologue who starts off with her preconceived notions and reverse-engineers to fit the data in a very misleading, untruthful way,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other contrarians, {like|